Free shipping on all orders over $ 500

SRT3109

Cat. No. M6271
SRT3109 Structure
Size Price Availability Quantity
5mg USD 315  USD350 In stock
10mg USD 495  USD550 In stock
50mg USD 1620  USD1800 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

SRT3109 is a CXCR2 ligand for use in the treatment of chemokine mediated diseases and conditions.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 475.53
Formula C18H23F2N5O4S2
CAS Number 1204707-71-0
Purity >98%
Solubility 10 mM in DMSO
Storage at -20°C
Related CXCR Products
LY2510924

LY2510924 is a potent and selective CXCR4 antagonist, which blocks SDF-1 binding to CXCR4 with IC50 of 0.079 nM.

Motixafortide (BL-8040)

Motixafortide (BL-8040) is an antagonist of CXCR4 with IC50 value of 1 nM.

ATI-2341 TFA

ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4).

SX-682

SX-682 is a potent and selective CXCR1/2 allosteric inhibitor, it may be useful for castration-resistant prostate cancer.

VUF11207 fumarate

VUF11207 fumarate is a CXCR7 agonist and a high-potency CXCR7 ligand (pKi=8.1).

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: SRT3109 supplier, CXCR, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.